Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2006-11-14
2006-11-14
Andres, Janet L. (Department: 1649)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S085100, C424S085200
Reexamination Certificate
active
07135181
ABSTRACT:
A method for in vivo down-regulation of amyloid protein in an animal, including a human being, the method comprising effecting presentation to the animal's immune system of an immunogenically effective amount of at least one amyloidogenic polypeptide or subsequence thereof which has been formulated so that immunization of the animal with the amyloidgenic polypeptide or subsequence thereof induces production of antibodies against the amyloidogenic polypeptide, and/or at least one analogue of the amyloidogenic polypeptide wherein is introduced at least one modification in the amino acid sequence of the amyloidogenic polypeptide which has as a result the immunization of the animal with the analogue induces production of antibodies against the amyloidogenic polypeptide.
REFERENCES:
patent: 4578770 (1986-03-01), Mitani
patent: 4596792 (1986-06-01), Vyas
patent: 4599230 (1986-07-01), Milich et al.
patent: 4599231 (1986-07-01), Milich et al.
patent: 4601903 (1986-07-01), Frasch
patent: 4608251 (1986-08-01), Mia
patent: 5192688 (1993-03-01), Switzer, III et al.
patent: 5200339 (1993-04-01), Abraham
patent: 5223482 (1993-06-01), Schilling, Jr.
patent: 5851996 (1998-12-01), Kline
patent: 5874469 (1999-02-01), Maniar et al.
patent: 6544518 (2003-04-01), Friede et al.
patent: 6713450 (2004-03-01), Frangione et al.
patent: 6787144 (2004-09-01), Schenk et al.
patent: 6787523 (2004-09-01), Schenk
patent: 6787637 (2004-09-01), Schenk
patent: 2002/0077288 (2002-06-01), Frangione et al.
patent: 2002/0187157 (2002-12-01), Jensen et al.
patent: 2003/0068325 (2003-04-01), Wang
patent: 2003/0086938 (2003-05-01), Jensen et al.
patent: 2003/0157117 (2003-08-01), Rasmussen et al.
patent: 2004/0062802 (2004-04-01), Hermelin
patent: 2004/0091945 (2004-05-01), Fitzer-Attas et al.
patent: 2004/0141958 (2004-07-01), Steinaa et al.
patent: 1656-1995 (1996-07-01), None
patent: WO 93/15760 (1993-08-01), None
patent: WO 93/23076 (1993-11-01), None
patent: WO 95/07707 (1995-03-01), None
patent: WO9505849 (1995-03-01), None
patent: WO9523166 (1995-08-01), None
patent: WO 96/13513 (1996-05-01), None
patent: WO 98/23635 (1998-04-01), None
patent: WO 99/24468 (1999-05-01), None
patent: WO9927944 (1999-06-01), None
patent: WO 00/05316 (2000-02-01), None
patent: WO 00/20027 (2000-04-01), None
patent: WO 00/72880 (2000-12-01), None
patent: WO 01/42306 (2001-06-01), None
patent: WO 01/62282 (2001-08-01), None
patent: WO 01/62284 (2001-08-01), None
patent: WO 02/34777 (2002-05-01), None
patent: WO 01/39796 (2002-06-01), None
Skolnick and Fetrow (2000) From Genes to Protein Strucuture and Function: Novel Applications of Compuational Approaches in the Genomic Era. Trends in Biotech 18(1); 34-39.
Jobling et al, Mol. Microbiol., 1991, 5(7):1755-67.
Jen et al. (1997) Preparation and Purification of antisera against different regions or isoforms of beta-amyloid precursor protein. Brain Research Protocols 2:23-30.
Demattos et al. (2001) “Peripheral Anti Abeta Antibody Alters CNS and Plasma Abeta Clearance and Decreases Brain Abeta Bruden in a Mouse Model of Alzheimer's Disease” PNAS 10: 1-6.
Perutz et al. (2002) “Amyloid Fibers are Water-Flled Nanotubes” PNAS 99(8): 5591-5595.
Munch and Robinson (2002) Potential neurotoxic inflammatory responses to Abeta vaccination in humans. J Neural Transm 109: 1081-1087.
Esiri (2001) Is an Effective Immune Intervention for Alzheimer's Disease in Prospect? Trends in Pharm Science 22(1): 2-3.
Younkin (2001) Amyloid beta Vaccination: Reduced Plaques and Improved Cognition. Nature Medicine 7(1):18-19.
Games et al. (1995) Alzheimer-type Neuropathology in Transgenic Mice overexpressing V717F beta-amyloid precursor protein. Nature 373(6514): 523-527.
Raso (1998) Immunotherapy of Alzheimer's Disease Immunotherapy Weekly. Abstract.
Schenk et al. (1999) Immunization with amyloid-beta attenuates Alzeimer-disease-like pathology in the PDAPP Mouse. Nature 400:173-177.
Small et al. (2001) Alzheimer's Disease and Abeta Toxicity: from top to bottom. Nat Rev Neurosci. 2(8): 595-8.
Chapman (2000) Model Behavior. Nature 408: 915-916.
Lemere et al. (2000) Nasal Abeta Tratment Induces anti-Abeta antibody production and decreases cerebal amyloid burden in PD-APP mice. Annals of the NY Acad. Sci. 920: 328-331.
Grubeck-Lobenstein et al. (2000) Immunization of beta-amyloid: could T-cell activation have a harmful effect? TINS 23: 114.
Friedland et al. (1997) Neuroimaging of Vessel Amyloid in Alzheimer's Disease in Cerebrovascular Pathology in Alzheimer's Disease, eds. de la Torre and Hachinski, New York Academy of Science, NY, NY.
Frenkel et al. (1998) N-terminal EFRH Sequence of Alzheimer's beta-amyloid peptide represents the epitope of its anti-aggregating antibodies. Journal of Neuroimmunology 88: 85-90.
Frenkel et al. (2000) Immunization against Alzheimer's beta-amyloid plaques via EFRH phage adminstration. PNAS 97(21) 11455-11459.
Frenkel et al. (1999) High Affinity Binding of Monoclonal Antibodies to the sequential epitope EFRH of beta-amyloid peptide is essential for modulation of fibrillar aggregation. Journal of Neuroimmunology 95: 136-142.
ELAN “Elan and AHP Provide an Update on the Phase 2A Clinical Trial of AN-1792.” Press Release (Jan. 28, 2002).
ELAN “Elan and Wyeth Provide Update on Status of Alzheimer's Collaboration” Press Release (Mar. 1, 2002).
Tanaka et al. (1998) NC-1900, an active Fragment analog of arginine vasopressin, improves learning and memory deficits induced by beta-amyloid protein in rats. European Journal of Pharmocology 352: 135-142.
Tennet et al. (1995) Serum amyloid P component precents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. PNAS 92: 4299-4303.
Chen et al. (1998) Neurodegenerative Alzheimer-like pathology in PDAPP 717V—F transgenic mice. Progress in Brain Research 117: 327-334.
Wells (1990) Additivity of Mutational Effects in Proteins. Biochemistry 29(37): 8509-8517.
Bork (2000) Powers and Pitfalls in Sequence Analysis: The 70% Hurdle. Genome Research 10: 398-400.
Doerks (1998) Protein Annotation: detective work for function prediction. TIG 14(6): 248-250.
Smith and Zhang (1997) The Challenges of genome sequence annotation or “The Devil is in the details”. Nature Biotechnology 15: 1222-1223.
Brenner (1999) Erros in genome annotation. TIG 15(4): 132-133.
Bork and Bairoch (1996) Go Hunting in sequence databases but watch out for the traps. TIG 12(10): 425-427.
Ngo et al. (1995) The Protein Folding Problem and Tertiary Structure Prediction. 433-506.
Sigurdsson et al. (2002) Immunization for Alzheimer's Disease. Drug Development Research 56: 135-142.
Selkoe et al. (Feb. 20, 1987) “Conservation of Brain Amyloid Proteins in Aged Mammals and Humans with Alzheimer's Disease.” Science 235(4791): 873-877.
Johnstone et al. (Jul. 1991) “Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog, polar bear and five other mammals by cross-species polymerase chain reaction analysis.” Molecular Brain Research 10(4): 299-305.
Eikelenboom et al. (2000) “Neuroinflammation and Alzheimer Disease: Clinical and Therapeutic Implications.” Alzheimer Disease and Associated Disorders 14(Suppl. 1): S54-S61.
Elan: News Jan. 28, 2002 “Elan and AHP provide an update on the phase 2A Clinical Trial of AN-1792.”
Bishop and Robinson (Nov./Dec. 2002) “The amyloid hypothesis: let sleeping dogmas lie?” Neurobiology of Aging 23(6): 1101-1105.
Buttini, Manuel et al., “Expression of human apolipoprotein . . . ”, The Journal of Neuroscience, Jun. 15, 1999, 19(12), pp. 4867-4880.
Clark, Lorraine N. et al., “Pathogenic implications of mutations . . . ”, Proc. Natl. Acad. Sci. USA, Oct. 1998, vol. 95, pp. 13103-13107.
Hsiao, Karen, “Transgenic mice expresssing . . . ”, Experimental Gerontology, vol. 33, 7-8,Nov./Dec. 1998 pp. 883-889.
Hutton, Mike et al., “Association of missense . . . ”, Nature, vol. 393, Jun. 18, 1998, pp. 702-705.
Lippa, C.F. et al., “
Jensen Martin Roland
Nielsen Klaus Gregorius
Rasmussen Peter Birk
Andres Janet L.
Birch & Stewart Kolasch & Birch, LLP
Emch Gregory S.
Pharmexa A/S
LandOfFree
Method for down-regulation of amyloid does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for down-regulation of amyloid, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for down-regulation of amyloid will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3650840